Similar articles

• Lack of benefit for the addition of androgen deprivation therapy to dose-escalated radiotherapy in the treatment of intermediate- and high-risk prostate cancer.

  Krauss D, Kestin L, Ye H, Brabbins D, Ghilezan M, Gustafson G, Vicini F, Martinez A. Krauss D, et al. Int J Radiat Oncol Biol Phys. 2011 Jul 15;80(4):1064-71. doi: 10.1016/j.ijrobp.2010.04.004. Epub 2010 Jun 26. Int J Radiat Oncol Biol Phys. 2011. PMID: 20584576
• Outcome analysis of 300 prostate cancer patients treated with neoadjuvant androgen deprivation and hypofractionated radiotherapy.

  Higgins GS, McLaren DB, Kerr GR, Elliott T, Howard GC. Higgins GS, et al. Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):982-9. doi: 10.1016/j.ijrobp.2006.02.029. Epub 2006 Jun 5. Int J Radiat Oncol Biol Phys. 2006. PMID: 16750310
• Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.

  Martinez AA, Demanes DJ, Galalae R, Vargas C, Bertermann H, Rodriguez R, Gustafson G, Altieri G, Gonzalez J. Martinez AA, et al. Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1322-31. doi: 10.1016/j.ijrobp.2004.12.053. Int J Radiat Oncol Biol Phys. 2005. PMID: 16029788
• High risk biochemical relapse and the timing of androgen deprivation therapy.

  Ryan CJ, Small EJ. Ryan CJ, et al. J Urol. 2006 Dec;176(6 Pt 2):S61-5. doi: 10.1016/j.juro.2006.06.072. J Urol. 2006. PMID: 17084171 Review.
• Dose escalated external beam radiotherapy versus neoadjuvant androgen deprivation therapy and conventional dose external beam radiotherapy for clinically localized prostate cancer: do we need both?

  Roach M 3rd. Roach M 3rd. Strahlenther Onkol. 2007 Dec;183 Spec No 2:26-8. doi: 10.1007/s00066-007-2011-8. Strahlenther Onkol. 2007. PMID: 18167004 Review.